# Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects

> **NCT03357939** · PHASE1 · COMPLETED · sponsor: **Shanghai Henlius Biotech** · enrollment: 220 (actual)

## Conditions studied

- Immune System Disorder

## Interventions

- **DRUG:** HLX03
- **DRUG:** adalimumab

## Key facts

- **NCT ID:** NCT03357939
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-12
- **Primary completion:** 2018-09-15
- **Final completion:** 2018-09-15
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2022-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03357939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03357939, "Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects". Retrieved via AI Analytics 2026-09-05 from https://api.ai-analytics.org/clinical/NCT03357939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*